Fibroblast Growth Factor 23 and Inflammation in CKD : Clinical Journal of the American Society of Nephrology

Journal Logo

Original Articles

Fibroblast Growth Factor 23 and Inflammation in CKD

Munoz Mendoza, Jair; Isakova, Tamara; Ricardo, Ana C.; Xie, Huiliang; Navaneethan, Sankar D.; Anderson, Amanda H.; Bazzano, Lydia A.; Xie, Dawei; Kretzler, Matthias; Nessel, Lisa; Hamm, L. Lee; Negrea, Lavinia; Leonard, Mary B.; Raj, Dominic; Wolf, Myles for the Chronic Renal Insufficiency Cohort

Author Information
Clinical Journal of the American Society of Nephrology 7(7):p 1155-1162, July 2012. | DOI: 10.2215/CJN.13281211
  • Free
  • SDC
  • SDC



Fibroblast growth factor 23 (FGF23) is a phosphate-regulating hormone primarily secreted by osteocytes (1). Levels of FGF23 increase as kidney function declines as a physiologic response to maintain normal serum phosphate levels and neutral phosphate balance (2). Although FGF23 helps to prevent hyperphosphatemia, elevated circulating levels are independently associated with vascular dysfunction (3), left ventricular hypertrophy (4), increased risk for ESRD, and death in patients with CKD (5,6). Recent data indicate that FGF23 contributes directly to the development of left ventricular hypertrophy, suggesting a plausible biologic basis for the observed association between elevated FGF23 and mortality (7). By establishing a direct pathogenic role for FGF23 excess in CKD, these data support the need to explore additional potential mechanisms of FGF23 toxicity that underlie the link between elevated FGF23 levels and adverse clinical outcomes.

CKD is associated with elevated levels of inflammatory markers (8,9), which in turn are associated with atherosclerosis (10), faster rates of CKD progression (11), and increased risk for death (9,12). These observations suggest that inflammation plays an important role in the pathophysiology of cardiovascular disease in CKD. Given the high prevalence of inflammation and FGF23 excess in CKD, and the observations that each predicts risk for adverse clinical outcomes, we hypothesized that elevated levels of FGF23 and inflammation are associated, which could serve as another mechanistic link between FGF23 and adverse outcomes. To date, one small study reported a relationship between higher FGF23 and C-reactive protein (CRP) levels in 145 patients with early CKD (13). We characterized the association between FGF23, CRP, and additional markers of inflammation in a cross-sectional analysis of the Chronic Renal Insufficiency Cohort (CRIC) study of individuals with CKD stages 2–4.

Materials and Methods

Description of the Cohort

The CRIC study is a multicenter, prospective cohort study of risk factors for cardiovascular disease and progression of CKD among individuals with CKD stages 2–4 (14). Adult participants (n=3612) age 21–74 years with an age-stratified estimated GFR (eGFR) of 20–70 ml/min per 1.73 m2 at the screening visit were enrolled. To have adequate representation of ethnic minorities, blacks were oversampled, and the ancillary Hispanic CRIC (HCRIC) study enrolled 327 additional Hispanic participants (15). Participants were excluded for pregnancy, New York Heart Association class III–IV heart failure, HIV infection, cirrhosis, myeloma, renal cancer, recent chemotherapy or immunosuppressive therapy, polycystic kidney disease, organ transplantation, or previous treatment with dialysis for at least 1 month. The institutional review board at each site approved the study, and all participants provided written informed consent.

Study Population

We evaluated 3879 of the 3939 total CRIC and HCRIC participants who had baseline plasma FGF23 measured. Data on baseline inflammatory markers were available for nearly all of these participants: IL-6 and TNF-α in 3878 participants, high-sensitivity CRP in 3877, and fibrinogen in 3855. Serum 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D) levels were available in a subset of 1502 and 1527 participants, respectively, at the year 1 follow-up visit.

Data Collection and Measurements

We analyzed the following data that were collected at the baseline visit: demographic characteristics, medical history, smoking status, body mass index (BMI), use of statins, and blood and urinary samples. We evaluated statin use because these agents reduce levels of inflammatory markers in CKD (16). Comprehensive metabolic panels and urinary biochemical panels were measured using standard assays. Urinary fractional excretion of phosphate was calculated as follows:

Plasma FGF23 was measured using the second-generation C-terminal assay that detects two epitopes in the C-terminus of FGF23 (Immutopics, San Clemente, CA; coefficient of variation [CV]<5%). Plasma parathyroid hormone (PTH) was measured using a total PTH assay, which detects both the 1–84 PTH molecule and 7–84 fragments (Scantibodies, Santee, CA; CV<5%). Serum 25D was quantified using liquid chromatography–mass spectroscopy (CV<5%), and serum 1,25D was measured by competitive chemiluminescent immunoassay (Heartland Assays, Ames, IA; CV<12%). Plasma IL-6 and TNF-α were determined by ELISA (R&D systems, Minneapolis, MN; CV < 15%). Plasma high-sensitivity CRP was quantified by particle-enhanced immunonephelometry (Dade Behring–Siemens Healthcare, CV<5%), and fibrinogen was measured by immunochemical reaction (Dade Behring– Siemens Healthcare, CV<5%). With the exception of the vitamin D assays, all tests were performed in the CRIC Study Central Laboratory at the University of Pennsylvania. Estimated GFR was based on the modified Modification of Diet in Renal Disease (MDRD) equation (17). A subset of 1409 participants had GFR measured directly using 125I iothalamate clearance (iGFR).

Statistical Analyses

Continuous variables were summarized as mean ± SD or median with interquartile range (IQR). Categorical variables were expressed as frequencies and proportions. We analyzed FGF23 on a continuous scale and after categorizing participants into quartiles. Because of their skewed distributions, FGF23, IL-6, CRP, TNF-α, and urinary albumin-to-creatinine ratio (UACR) were natural log (ln)-transformed. We evaluated the associations between FGF23 and other mineral metabolites with markers of inflammation using Spearman correlations. We used separate linear regression models to examine the univariate and multivariable-adjusted association between FGF23 as primary exposure, and individual inflammatory markers (including IL-6, CRP, TNF-α, and fibrinogen) as the dependent variables. Multivariable analyses were adjusted for factors known to be associated with inflammation, including age, sex, race (black versus nonblack), ethnicity (Hispanic versus non-Hispanic), diabetes, current smoking, BMI, use of statins, eGFR, and lnUACR. In secondary analyses, we further adjusted for lnPTH and phosphate levels. To assess whether FGF23 was associated with inflammatory markers independent of vitamin D, we adjusted for 25D and 1,25D separately in the subset of patients in whom these data were available. We also repeated the adjusted analyses in the subcohort of participants with iGFR, substituting iGFR for MDRD eGFR in the multivariable models.

In CKD, elevated BMI is associated with reduced serum phosphate levels (18) and elevated FGF23 levels (19). Therefore, we performed formal tests for interaction between BMI and FGF23 and analyzed models stratified by BMI as lean (<25 kg/m2), overweight (25 to <30 kg/m2) and obese (≥30 kg/m2) (20). Finally, we used logistic regression to determine whether elevated FGF23 levels are independently associated with presence of severe inflammation, defined as being in the highest 25th percentile of plasma concentration of each inflammatory marker (IL-6, CRP, TNF-α, and fibrinogen). We adjusted for the same covariates as in the primary analyses. Two-sided P values < 0.05 were considered to represent a statistically significant difference, unless otherwise noted. We performed analyses using SAS EG, version 9.2 (SAS Institute, Cary, NC).


Baseline characteristics of the 3879 CRIC participants categorized by FGF23 quartiles are presented in Table 1. Compared with lower FGF23 quartiles, participants in the upper quartiles were more likely to be female, to be smokers, and to have diabetes and a higher BMI. In addition to serum creatinine, phosphate, PTH, fractional excretion of phosphate, and UACR, levels of all inflammatory markers (CRP, IL-6, TNF-α, and fibrinogen) increased monotonically while 25D, 1,25D, and eGFR decreased with ascending FGF23 quartiles.

Table 1:
Baseline characteristics of participants according to fibroblast growth factor 23 quartiles

Table 2 presents the correlation coefficients between markers of mineral metabolism and inflammation. Among the mineral metabolites, FGF23 showed the strongest correlation with each inflammatory marker. Only BMI exceeded FGF23 in strength of correlation with CRP, and only eGFR surpassed it for TNF-α. In contrast, FGF23 was the strongest correlate of IL-6 and fibrinogen levels.

Table 2:
Spearman correlation coefficients between markers of mineral metabolism and inflammation

In univariate and multivariable-adjusted linear regression analyses, increasing lnFGF23 and ascending FGF23 quartiles were significantly associated with lnIL-6, lnCRP, lnTNF-α, and fibrinogen (Table 3). The results were qualitatively unchanged in models that further adjusted for lnPTH and phosphate (Table 3), in models that adjusted for 25D and 1,25D levels in participants with available levels (n=1502), and when we substituted iGFR (n=1409) for eGFR (Supplemental Tables A and B).

Table 3:
Univariate and multivariate linear regression analyses between inflammatory markers as dependent variables and fibroblast growth factor 23 as primary exposure

Significant interaction was detected between BMI and lnFGF23 (P=0.02) in the multivariable-adjusted model of lnCRP. In analyses stratified by BMI (<25, 25–29.9, ≥30 kg/m2), unadjusted median levels of CRP increased across FGF23 quartiles and BMI categories in a synergistic pattern: Participants in the highest FGF23 and BMI group had the highest CRP level (Figure 1A). Similar interaction was found between BMI and lnFGF23 (P=0.04) in the multivariable-adjusted model of lnTNF-α. Although similar analyses of lnIL-6 and fibrinogen did not reach significance (P>0.05), unadjusted median levels of IL-6 demonstrated a trend similar to that seen for CRP (Figure 1B).

Figure 1:
Median inflammatory marker levels across fibroblast growth factor 23 (FGF23) quartiles and body mass index (BMI) categories. (A) C-reactive protein (CRP). (B) IL-6. Q1, FGF23 quartile 1 (<95.8 RU/ml); Q2, FGF23 quartile 2 (95.8 to <145.4 RU/ml); Q3, FGF23 quartile 3 (≥145.5 to <239.1 RU/ml); Q4, FGF23 quartile 4 (≥ 239.2 RU/ml).

One hundred thirty-five participants (3.5%) had plasma concentrations of IL-6, CRP, TNF-α, and fibrinogen in the highest 25th percentile for each analyte and were thus classified as severely inflamed. LnFGF23 was a strong independent risk factor for severe inflammation in univariate (odds ratio [OR], 2.4 per 1-unit higher lnFGF23 [95% confidence interval (CI), 2.0–2.9]) and multivariable-adjusted (OR, 2.0 per 1-unit higher lnFGF23 [95% CI, 1.6–2.5]) logistic regression analyses. This independent relationship was unchanged in models that further adjusted for lnPTH and phosphate (OR, 2.0 per 1-unit higher lnFGF23 [95% CI, 1.5–2.5]). Figure 2 demonstrates the monotonic higher odds of severe inflammation according to ascending quartiles of FGF23 (P for trend < 0.001 for all models). In contrast, lnPTH and phosphate were not associated with severe inflammation in multivariable-adjusted models (data not shown).

Figure 2:
Crude and multivariable-adjusted logistic regression analyses evaluating the association between fibroblast growth factor 23 (FGF23) with severe inflammation. Severe inflammation was defined as being in the highest 25th percentile of each of the IL-6, C-reactive protein, TNF-α, and fibrinogen (n=135) distributions. Error bars indicate 95% confidence intervals. aAdjusted for age, sex, black race, Hispanic ethnicity, diabetes, current smoking, body mass index (BMI), use of statins, estimated GFR, and urinary albumin-to-creatinine ratio. bAdjusted for values in model A plus further adjustment for phosphate and parathyroid hormone. P for trend < 0.001 for all three models. Q1, FGF23 quartile 1 (<95.8 RU/ml); Q2, FGF23 quartile 2 (95.8–145.4 RU/ml); Q3, FGF23 quartile 3 (145.5–239.1 RU/ml); Q4, FGF23 quartile 4 (≥239.20 RU/ml).


Among patients with CKD, elevated levels of FGF23 are independently associated with higher levels of CRP, IL-6, TNF-α, and fibrinogen and with substantially greater odds of manifesting severe inflammation. The associations were independent of renal function, measures of mineral metabolism, and other factors that are known to be associated with inflammation. Furthermore, among the mineral metabolites we tested, FGF23 was most strongly correlated with each inflammatory marker, and FGF23 but not PTH or phosphate was associated with greater odds for severe inflammation in multivariable models. Given the associations between inflammation, atherosclerosis, and vascular calcification (21), and that some studies have shown association between elevated FGF23 and calcification in CKD and ESRD (22,23), these results provide new insight into another potential mechanism underlying the strong associations between elevated FGF23, cardiovascular disease, and mortality. Further studies are needed to determine whether FGF23 might contribute to atherosclerosis and vascular calcification by stimulating inflammation or whether inflammation might contribute to the development of vascular disease through effects on FGF23.

Our results are consistent with prior reports of a direct association between elevated FGF23 and CRP levels in patients with CKD not yet on dialysis (13), and in patients with ESRD undergoing hemodialysis (24). Our results are also consistent with those of prior studies that reported associations between serum phosphate and inflammatory markers in patients with CKD stages 3–4 (25) and those with ESRD (26). These studies did not measure FGF23; however, given the known correlation between elevated phosphate and FGF23 levels, these findings support the link between FGF23 and inflammation that we observed.

Several mechanisms could underlie the cross-sectional association between elevated levels of FGF23 and inflammatory markers. Elevated FGF23 could stimulate inflammation indirectly by reducing levels of 1,25D. FGF23 reduces circulating levels of 1,25D by inhibiting renal 1-hydroxylase and by stimulating 24-hydroxylase, which accelerates degradation of 1,25D (27,28). Because reduced 1,25D levels are associated with higher IL-6 levels (29), and treatment with vitamin D receptor analogues decreased CRP levels in CKD (30), it is possible that FGF23-mediated suppression of 1,25 is pro-inflammatory. Although the lack of change in the associations between FGF23 and inflammatory markers after adjustment for 1,25D levels might be considered contrary to this hypothesis, the vitamin D analyses were partially limited by their different time of measurement.

Another possibility is that FGF23 directly induces inflammation. Our group recently reported that FGF23 is capable of inducing signaling in cells that do not express klotho, the FGF23 co-receptor in the kidney, via activation of FGF receptors, which are present in the liver (7), and adipose tissue (31). Thus, it is possible that FGF23 could induce expression of hepatic-derived inflammatory markers, such as CRP (32), or fat-derived cytokines, such as IL-6 and TNF-α (33,34), through klotho-independent effects. Further studies are needed to investigate whether another off-target effect of FGF23 is to simulate expression of pro-inflammatory cytokines in adipocytes and hepatocytes. Alternatively, because klotho may have anti-inflammatory properties (35) and its renal expression is reduced in patients with CKD (36), klotho deficiency might mediate the association between FGF23 excess and inflammation. Reduced klotho expression may be a mechanism or a consequence of elevated FGF23 levels in CKD (2,37). The main limitations to addressing the role of klotho at present are the lack of a reliable in vivo assay for circulating klotho and incomplete understanding of the relative physiologic effects of soluble klotho versus the cell-based transmembrane form.

A third possibility is that inflammation stimulates FGF23. This form of reverse causality could result from the direct bone resorptive effects of inflammation (38), which could stimulate FGF23 production (39). Alternatively, functional iron deficiency induced by inflammation-mediated secretion of hepcidin, which inhibits intestinal absorption of iron and prevents its release from macrophages and hepatic stores for erythropoiesis (40), could drive increased FGF23 levels. Indeed, iron deficiency induces transcription of FGF23, which is cleaved intracellularly, leading to elevated circulating levels of C-terminal FGF23 but normal intact levels (unless patients carry the activating FGF23 mutation of autosomal-dominant hypophosphatemic rickets) (41,42). Of note, no studies have examined the regulation of FGF23 secretion in osteocytes by disordered iron metabolism in CKD. Future studies should measure both intact and C-terminal FGF23 levels in CKD patients with varying degrees of inflammation and iron deficiency.

We confirmed the strong correlation between obesity and inflammation and demonstrated that BMI modifies the association between lnFGF23 and lnCRP and TNF-α. Adipose tissue produces IL6 and TNF-α (33,34), and IL-6 is a major stimulus of CRP synthesis in hepatocytes (32). Adipocytes also produce leptin to regulate energy intake and energy expenditure (43). Interestingly, leptin levels are elevated in obesity (44) and in CKD (43,45) and correlate with inflammation and adiposity in CKD (45), suggesting a potential link between inflammation, adiposity, and elevated leptin levels. Furthermore, elevated FGF23 is associated with elevated leptin levels (19), and leptin injection induced secretion of FGF23 in leptin-ablated mice (46), suggesting a potential link between FGF23 and leptin. Thus, we can speculate that leptin may mediate the association between elevated FGF23 and inflammation. Further studies are needed to test this hypothesis.

This study has limitations. The cross-sectional design precludes the establishment of a causal relationship or the direction of the association between FGF23 and inflammation. Although our results and those of a previous study support the hypothesis that FGF23 is associated with inflammation (13), we cannot exclude unmeasured confounders. Although renal function was estimated using the MDRD eGFR formula in the primary analysis, a subanalysis using only participants with iGFR showed similar results. Vitamin D levels were not available in all participants, but adjustments for this confounder in the subset with available levels did not alter the results. We used a single measure of FGF23 and inflammatory markers that may not accurately reflect long-term FGF23 levels and inflammatory status. However, because random misclassification due to biologic variability will lead to underestimation of true associations, this limitation is unlikely to explain our findings. Finally, we defined severe inflammation according to the distribution of values observed in our population (quartiles) rather than on clinically relevant cut-points that are currently unknown in CKD.

In conclusion, the current study shows that higher FGF23 levels are independently associated with higher levels of inflammatory markers in patients with CKD and with significantly greater odds of severe inflammation. Future studies should evaluate whether inflammation modifies the association between elevated FGF23 levels and adverse clinical outcomes in CKD.


M.W. has served as a consultant or received honoraria from Abbott Laboratories, Genzyme, and Luitpold and research support from Amgen and Shire. No other conflicts of interest were disclosed.


This CRIC ancillary study was supported by National Institutes of Health Grants DK081374-S1 (J.M.M.), R01DK081374 (M.W.), K23DK087858 (T.I.), and R01DK073665 (D.R.). The CRIC study is supported by Cooperative Agreement Project Grants 5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028, 5U01DK60980, 5U01DK060963, and 5U01DK060902 from the National Institute of Diabetes and Digestive and Kidney Diseases and by Grants UL1RR024134, UL1RR025005, M01RR16500, UL1RR024989, M01RR000042, UL1RR024986, UL1RR029879, RR05096, and UL1RR024131 from the National Institutes of Health.

Published online ahead of print. Publication date available at

This article contains supplemental material online at

See related editorial, “Fibroblast Growth Factor 23, Cardiovascular Disease, and Inflammation,” on pages 1061–1062.


1. Quarles LD: Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118: 3820–3828, 2008
2. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370–1378, 2011
3. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C: FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78: 679–685, 2010
4. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545–2552, 2009
5. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584–592, 2008
6. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf MChronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432–2439, 2011
7. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393–4408, 2011
8. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107: 87–92, 2003
9. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, Choukroun G, Vanholder R, Massy ZAEuropean Uremic Toxin Work Group (EUTox): Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77: 550–556, 2010
10. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899–1911, 1999
11. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan GCholesterol and Recurrent Events (CARE) Trial Investigators: Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68: 237–245, 2005
12. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 99–102, 2002
13. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G: Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 21: 1853–1861, 2010
14. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JTChronic Renal Insufficiency Cohort (CRIC) Study Investigators: The Chronic Renal Insufficiency Cohort (CRIC) study: Design and methods. J Am Soc Nephrol 14[Suppl 2]: S148–S153, 2003
15. Fischer MJ, Go AS, Lora CM, Ackerson L, Cohan J, Kusek JW, Mercado A, Ojo A, Ricardo AC, Rosen LK, Tao K, Xie D, Feldman HI, Lash JPCRIC and H-CRIC Study Groups: CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. Am J Kidney Dis 58: 214–227, 2011
16. Ridker PM, MacFadyen J, Cressman M, Glynn RJ: Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 55: 1266–1273, 2010
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth DModification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461–470, 1999
18. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, Hegarty J, New J, O’Donoghue DJ, Middleton RJ, Kalra PA: Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 5: 2251–2257, 2010
19. Mirza MA, Alsiö J, Hammarstedt A, Erben RG, Michaëlsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellström D, Lind L, Ohlsson C, Larsson TE: Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 31: 219–227, 2011
20. Aronne LJ: Classification of obesity and assessment of obesity-related health risks. Obes Res 10[Suppl 2]: 105S–115S, 2002
21. Moe SM, Chen NX: Inflammation and vascular calcification. Blood Purif 23: 64–71, 2005
22. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZAon behalf of the European Uremic Toxin (EUTox) Work Group: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages [Published online ahead of print November 23, 2011]. Osteoporos Int doi:
23. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: Peripheral vascular calcification in long-haemodialysis patients: Associated factors and survival consequences. Nephrol Dial Transplant 24: 948–955, 2009
24. Ashikaga E, Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, Nagai H, Matsumoto K, Kato N, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T: Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial 14: 315–322, 2010
25. Navarro-González JF, Mora-Fernández C, Muros M, Herrera H, García J: Mineral metabolism and inflammation in chronic kidney disease patients: A cross-sectional study. Clin J Am Soc Nephrol 4: 1646–1654, 2009
26. Movilli E, Feliciani A, Camerini C, Brunori G, Zubani R, Scolari F, Parrinello G, Cancarini GC: A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients. Nephron Clin Pract 101: c161–c167, 2005
27. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975–980, 2010
28. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429–435, 2004
29. Isakova T, Gutiérrez OM, Patel NM, Andress DL, Wolf M, Levin A: Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 21: 295–302, 2011
30. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 52: 249–255, 2008
31. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M: Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282: 26687–26695, 2007
32. Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 242: 237–239, 1989
33. Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, Lindholm B, Cederholm T, Stenvinkel P: Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 80: 1222–1229, 2004
34. Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15: 2792–2800, 2004
35. Maekawa Y, Ishikawa K, Yasuda O, Oguro R, Hanasaki H, Kida I, Takemura Y, Ohishi M, Katsuya T, Rakugi H: Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine 35: 341–346, 2009
36. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K, Kishimoto T, Kinoshita S, Kuroki T, Nabeshima Y: Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 280: 1015–1020, 2001
37. Kuro-o M: Klotho in chronic kidney disease—what’s new? Nephrol Dial Transplant 24: 1705–1708, 2009
38. Dai JC, He P, Chen X, Greenfield EM: TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone 38: 509–520, 2006
39. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D: Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150: 4835–4845, 2009
40. Ganz T: Molecular control of iron transport. J Am Soc Nephrol 18: 394–400, 2007
41. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ: Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 95: 1846–1850, 2010
42. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE: Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 108: E1146–E1155, 2011
43. Mantzoros CS: Leptin in renal failure. J Ren Nutr 9: 122–125, 1999
44. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292–295, 1996
45. Nordfors L, Lönnqvist F, Heimbürger O, Danielsson A, Schalling M, Stenvinkel P: Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 54: 1267–1275, 1998
46. Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N: Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 25: 1711–1723, 2010
Copyright © 2012 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.